Glen Eagle Advisors, LLC Biomea Fusion, Inc. Transaction History
Glen Eagle Advisors, LLC
- $604 Billion
- Q1 2025
A detailed history of Glen Eagle Advisors, LLC transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 250 shares of BMEA stock, worth $365. This represents 0.0% of its overall portfolio holdings.
Number of Shares
250
Previous 250
-0.0%
Holding current value
$365
Previous $970,000
45.05%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BMEA
# of Institutions
109Shares Held
16.1MCall Options Held
229KPut Options Held
354K-
Cormorant Asset Management, LP Boston, MA3.57MShares$5.21 Million0.81% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$3.42 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.38MShares$2.01 Million0.0% of portfolio
-
Aisling Capital Management LP New York, NY799KShares$1.17 Million0.59% of portfolio
-
Geode Capital Management, LLC Boston, MA626KShares$913,8910.0% of portfolio
About Biomea Fusion, Inc.
- Ticker BMEA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,290,600
- Market Cap $42.8M
- Description
- Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...